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Urinary tract infections (UTIs) are one of themost common pathological conditions in both
community and hospital settings. It has been estimated that about 150 million people
worldwide develop UTI each year, with high social costs in terms of hospitalizations and
medical expenses. Among the common uropathogens associated to UTIs development,
UroPathogenic Escherichia coli (UPEC) is the primary cause. UPEC strains possess
a plethora of both structural (as fimbriae, pili, curli, flagella) and secreted (toxins,
iron-acquisition systems) virulence factors that contribute to their capacity to cause
disease, although the ability to adhere to host epithelial cells in the urinary tract represents
the most important determinant of pathogenicity. On the opposite side, the bladder
epithelium shows a multifaceted array of host defenses including the urine flow and
the secretion of antimicrobial substances, which represent useful tools to counteract
bacterial infections. The fascinating and intricate dynamics between these players
determine a complex interaction system that needs to be revealed. This review will focus
on the most relevant components of UPEC arsenal of pathogenicity together with the
major host responses to infection, the current approved treatment and the emergence
of resistant UPEC strains, the vaccine strategies, the natural antimicrobial compounds
along with innovative anti-adhesive and prophylactic approaches to prevent UTIs.
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URINARY TRACT INFECTIONS (UTIs)
Urinary tract infections (UTIs) are widespread and affect a large proportion of the human
population. About 150 million people worldwide develop UTI each year, with high social costs
(Flores-Mireles et al., 2015). It is estimated that 40% of women develop at least one UTI during
their lifetime (Micali et al., 2014) and that 11% of women over 18 years have an episode of UTI per
year (Foxman and Brown, 2003; Foxman, 2014). With roughly eleven-million cases reported in the
sole U.S. each year, the costs are estimated $5 billion annually (Figure 1) (Foxman, 2014).
The UTI refers to the presence of a certain number of bacteria in the urine (generally > 105/ml)
and symptomatic UTIs are classified in order of severity as urosepsis syndrome, pyelonephritis (or
upper UTI, with infection in the kidney) and cystitis (or lower UTI, with bacteria into the bladder;
Foxman, 2014; Smelov et al., 2016). Clinically, UTIs classification comprises either uncomplicated
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or complicated cases, depending on the presence of structural or
neurological urinary tract abnormalities (Zacché and Giarenis,
2016). The ORENUC system classifies the risk factors according
to the phenotype (Johansen et al., 2011): O, no known risk
factors; R, risk of recurrent UTIs without a more severe
outcome; E, extraurogenital risk factors;N, relevant nephropathic
diseases; U, urologic resolvable (transient) risk factors; C,
permanent external urinary catheter and unresolved urologic
risk factors (see also Smelov et al., 2016 for a modified
classification). The susceptibility to develop an UTI phenotype
is related to several factors, as dysfunctions of the urinary tract
and/or genetic mechanisms involved in the innate immune
response control to infections (Koves and Wullt, 2016). In
particular, the innate immune system may respond either
to UPEC patterns (pathogen-associated molecular patterns;
PAMPs) or to molecules derived from damaged or dying
cells (danger/damage-associated molecular patterns; DAMPs).
Pattern recognition receptors (PRRs) recognized these patterns
in specialized immune cells, epithelia, and other tissues (Purves
and Hughes, 2016). Assembling in the cytosol of multimeric
protein complexes (inflammasomes) occurs after sensing PAMPs
or DAMPs structures that can be formed in both upper and lower
urinary tract (Guo et al., 2015). They trigger innate immune
responses through mechanisms depending or not from the
production of proinflammatory cytokines (Purves and Hughes,
2016).
The bacterial cystitis (also called acute cystitis) can occur
in both women and men and some people develop recurrent
infections of the urinary tract (Fiore and Fox, 2014). Three
or more urinary tract infections within 12 months define the
recurring UTI, as well as two or more recurrences within
6 months. The same bacterial species that caused previous
infection is typically responsible for relapses. Approximately
20–30% of adult women with an initial UTI will experience a
recurrence within 3–4 months; whereas, in children, about one
third experiencing a UTI before the age of one, will experience
a recurrence within 3 years, and 18% of them will have a
recurrence within a few months (Nuutinen and Uhari, 2001).
However, these figures are understated; in fact, about 50% of
UTI does not come to medical attention. Recurrent UTIs can
be introduced from different sources and the same or different
UTI-causing strains in the gut are able to (re)inoculate the
bladder. Alternatively, bacteria residing in the bladder epithelium
are able to re-emerge periodically and cause UTI recurrence
(Silverman et al., 2013). In patients suffering from recurrent
UTIs, maintenance is ensured by antibiotic prophylaxis; however,
in some cases UTI needs to be treated by surgery (Tolg and Bagli,
2012). During pregnancy, recurrent UTIs may be frequent and
can cause severe adverse outcomes for the mother and the baby,
including preterm birth. The interventions in this setting can be
pharmacologic (antibiotics) or non-pharmacological (alternative
remedies; Schneeberger et al., 2012). In pre-menopausal women,
sexual activities three or more times a week, the use of
spermicides, new or multiple sexual partners and having suffered
from UTI before age 15 are the main risk factors in UTI
development and recurrence. In menopausal women, systemic
hormonal therapy is not an effective prevention and usually
asymptomatic bacteriuria during this period does not require
treatment (Milart et al., 2013). In women after menopause, the
risk increases mainly by low estrogen levels after-effects, which
are often associated to vaginal atrophy (Arnold et al., 2016).
In women over the age of 61–65 years, half have suffered of
genital-urinary symptoms while 29% had episodes of urinary
incontinence, all symptoms associated with bacteriuria (Raz,
2001).
UROPATHOGENIC ESCHERICHIA COLI
AND ITS VIRULENCE
UPEC is the main cause of community-acquired UTIs (about 80–
90%; Foxman, 2014; Flores-Mireles et al., 2015). FourmainUPEC
phylogroups (A, B1, B2, and D) have been identified on the basis
of the occurrence of genomic Pathogenicity Islands (PAI) and the
expression of virulence factors, such as adhesins, toxins, surface
polysaccharides, flagella, and iron-acquisition systems (Bien
et al., 2012). Usually, many of these virulence factors are required
for UPEC to cause UTI (Hannan et al., 2012). However, besides
UPEC, UTI can be caused by Klebsiella pneumoniae (about
7%), Proteus mirabilis (about 5%), and Pseudomonas aeruginosa,
Enterococcus faecalis, Enterobacter cloacae, Streptococcus bovis,
and the fungus Candida albicans (for the remaining percentage;
Parish and Holliday, 2012; Palou et al., 2013; Hof, 2017). During
UTIs, UPEC pathogenesis includes: (a) UPEC colonization of the
periurethral and vaginal areas with colonization of the urethra;
(b) ascending into the bladder lumen and growth as plantktonic
cells in urine; (c) adherence to the surface and interaction with
the bladder epithelium defense system (see below); (d) biofilm
formation; (e) invasion and replication by forming bladder
Intracellular Bacterial Communities (IBCs) where quiescent
intracellular reservoirs (QIRs) form and reside in the underlying
urothelium; (f) kidney colonization and host tissue damage with
increased risk for bacteremia/septicemia.
Replication of bacteria in the IBC can easily reach as many as
105 bacteria per cell; furthermore, bacteria in the IBC undergo
morphological changes, flux out of the infected cell, and go
onto infect neighboring cells (Dhakal et al., 2008; Flores-Mireles
et al., 2015; Spaulding and Hultgren, 2016). The flushing of urine
removes most of the invading bacteria, along with UPEC-filled
exfoliated bladder epithelium cells (BECs; Kaper et al., 2004).
UPEC colonize the bladder using a variety of virulence
factors that therefore play critical roles in UTI pathogenesis.
These include surface structural components, such as
lipopolysaccharide (LPS), polysaccharide capsule, flagella,
outer-membrane vesicles, pili, curli, non-pilus adhesins, outer-
membrane proteins (OMPs), as well as secreted toxins, secretion
systems, and TonB-dependent iron-uptake receptors, including
siderophore receptors (Figure 2). All of these components are
attractive candidates for the development of new drugs and
vaccines (Klemm et al., 2010; Werneburg et al., 2015; O’Brien
et al., 2016).
LPS are molecules with amphipathic properties consisting of
fatty acids lined to an oligosaccharide core, which in turn is
bound to a long polysaccharide chain commonly called O antigen
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FIGURE 1 | The urinary tract and sites of infection.
FIGURE 2 | Escherichia coli adhesins and harboring/motile structures.
(Simpson et al., 2015). LPS structural constituents mediate
multiple aspects of the UPEC life cycle, including the ability to
acutely colonize bladders, form reservoirs, and evoke innate and
adaptive immune responses (Aguiniga et al., 2016). LPS provide
resistance against hydrophobic antibiotics and hypersensitivity
to hydrophobic toxic molecules (such as bile salts and some
antibiotics) occurs when the amount of LPS at the cell surface
is decreased (Zhang et al., 2013).
In UPEC, the fim operon encodes type 1 pili (expressing an
hemagglutination which is mannose-sensitive), whereas the pap
operon encodes P- or Pap-pili (which are able to interact with
the digalactoside unit in the P-blood group antigen). In UPEC
clinical isolates, fim operon is constitutive whereas pap is part
of a PAI that is also responsible for other putative virulence
determinants. Generally, both types of pili are heteropolymeric
consisting of a major pilus protein subunit that provides the
pilus stalk and several minor subunit proteins at the distal
end, with PapG and FimH representing the actual adhesins.
PapG and FimH are composed by two domains, the first allows
copolymerization and is made by a pilin domain, whereas the
second is a lectin domain able to bind carbohydrates (Kline et al.,
2009). The chaperone-usher (CU) pathway assembles pili. More
than 1,000 copies of the FimA major pilin form the type 1–
pilus rod, while at its distal end the pilus tip contains the FimH
adhesin followed by single copies of the FimG and FimF adaptor
subunits. Mannosylated proteins that are present on the bladder
epithelium bind to FimH in a Rho GTPases (Rac1)-mediated
host actin cytoskeleton rearrangement-dependent manner (Eto
et al., 2007). This eventually leads to the development of cystitis
due to bacterial invasion (Figure 2; Hahn et al., 2002). In
addition, the expression of type 1 pili is strictly controlled by
phase variation, which reversibly switches between the type
1 pili active expression (Phase-ON, piliated cells) and loss
of expression (Phase-OFF, non-piliated cells; Schwan, 2011).
Molecular pathways, which are involved in reversible switching
between ON-OFF Phases, are strictly regulated by environmental
signals within the urinary tract such as acidic pH and salt growth
conditions.
Six different subunits which are arranged into two distinct
subassemblies (the tip fibrillum and the pilus rod) form the P
pilus. At the distal end, the tip fibrillum is composed of one
PapG adhesin followed by PapF and PapE subunits. The pilus
rod is made by more than 1,000 copies of the PapA subunit. The
adaptor subunit PapK connects the above subunits to the PapA
rod, which is a superhelical structure at the base of the pilum
(Figure 2; Busch and Waksman, 2012).
Curli are bacterial surface appendages that secrete subunits
from the cell as soluble monomeric proteins and possess the
typical structure and physical characteristics of amyloid fibrils.
which are known to be formed in some human degenerative
diseases. The bacterial amyloids may facilitate biofilm formation
(Goyal et al., 2014). In UPEC, curli formation is coordinated
by proteins encoded in the operons csg DEFG. The operon-
accessory proteins CsgE, CsgF, and CsgG are required to facilitate
the secretion of CsgA whereas CsgB nucleates CsgA subunits
into curli fibers (Figure 2; Chapman et al., 2002; Barnhart and
Chapman, 2006).
While pili are involved in the initial attachment of UPEC
to the urinary tract mucosa, UPEC elaborate numerous other
afimbrial ahesins. In fact, the adhesin TosA is present in about
30% of urinary tract isolates and is expressed during UTI (Vigil
et al., 2011). Another adhesin, FdeC, is involved in colonization
of the bladder and kidneys in a mouse model of infection (Nesta
et al., 2012), whereas the iron-regulated adhesin Iha mediates
adherence to BECs (Johnson et al., 2005).
Moreover, the large majority of UPEC isolated from women
with acute, asymptomatic, or recurrent UTIs shows the presence
of flagellum-mediated motility (Wright et al., 2005). Flagella
(Figure 2) are organelles that confer adhesive and invasive
properties to some EPEC strains (Giron et al., 2002) and play
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a key role in the dynamic of biofilms (Pratt and Kolter, 1998).
It was recently reported that during biofilm formation, flagella
play different roles such as adherence, maturation, and dispersal
as shown by gene expression and regulation during the growth
phase (Nakamura et al., 2016).
On the other hand, UPEC toxins play different pathogenetic
roles during infection. The α-hemolysin is in fact associated with
renal damage and scarring, induces Ca2+ oscillations in renal
tubular epithelial cells, thereby potentially enhancing ascension
and colonization of ureters and kidney parenchyma by disrupting
the normal flow of urine. Recently (Nagamatsu et al., 2015),
α-hemolysin was found to induce proinflammatory Caspase-
1/Caspase-4-dependent cell death in bladder epithelial cells,
resulting in cell exfoliation (see below).
UPEC toxins, adhesins, enzymes, and non-protein antigens
like LPS are not released as soluble molecules; rather, they are
associated with outer-membrane vesicles, which bud off the
surface of Gram-negative bacteria during all stages of growth
(Figure 2; Ellis and Kuehn, 2010). The formation of membrane
vesicles is considered a “smart” way to protect bacterial toxins
and an efficient system to deliver them into host cell (Wiles et al.,
2008).
Iron acquisition is a critical requirement for UPEC survival
in an environment that is iron-limited as the urinary tract
(Skaar, 2010). Thus, is not suprising that IBC UPEC show
upregulation of redundant systems for the acquisition of iron
(Reigstad et al., 2007). In this regard, siderophores are small-
molecule iron chelators that are produced by UPEC strains to
scavenge ferric iron (Fe3+), thus UPEC express yersiniabactin,
salmochelin, and aerobactin. Siderophore receptors require the
TonB cytoplasmic membrane-localized complex, a high-affinity
iron acquisition system that allows binding and chelation of iron
at the cell surface to promote its uptake (O’Brien et al., 2016).
However, uroepithelial cells, to prevent bacterial iron
scavenging, upregulate genes for the transferrin receptor and for
lipocalin 2.
Lastly, further UPEC factors associated with colonization have
been linked to the regulation of metabolic pathways mediated by
two-component signaling systems (TCSs). TCSs are main signal
transduction pathways by which bacteria sense and respond
to a wide array of environmental stimuli, including quorum
sensing signals, nutrients, antibiotics. TCSs are composed
by a membrane-bound sensor histidine kinase (HK) and a
cytoplasmic response regulator (RR) that functions by regulating
gene expression (Stock et al., 2000). Among UPEC-associated
TCSs involved in UTI pathogenesis, the BarA/UvrY system has
been described to regulate switching between glycolytic and
gluconeogenic pathways (Tomenius et al., 2006) the EvgS/EvgA
and PhoQ/PhoP systems have been involved in acid resistance
(Eguchi et al., 2011), while the function of KguS/KguR is in the
control of the utilization of α-ketoglutarate. In this way they
facilate the adaptation of UPEC in the urinary tract (Cai et al.,
2013).
The importance of the above described UPEC virulence
factors in UTI pathogenesis has been further supported, in recent
years, by the application of multiple “omics” technologies aimed
at investigating the UPEC genomic diversity, the global gene
expression in different models of infection both in vitro and in
vivo, and to define the occurrence of UPEC-specific proteins
as new candidate therapeutic and vaccine targets (as recently
reviewed by Lo et al., 2017).
Next-generation sequencing (NGS) technologies are
providing rapid low-cost determination of UPEC genomes
useful to monitor outbreaks, epidemiology of emerging strains,
as well as evolution of resistance (Petty et al., 2014; Stoesser
et al., 2016). On the other hand, analysis of different UPEC
genomes and the comparison with the E. coli genomic database
revealed the plasticity of UPEC pan genome, and the presence of
UPEC-specific PAIs genes predicted to encode putative virulence
factors, such as pilus proteins, adhesins, and iron-uptake systems
(Moriel et al., 2016).
Transcriptomics investigations by bothmicroarrays andNGS-
based RNA sequencing (RNA-seq), on the other hand, has led to
the identification of virulence and fitness UPEC genes, expressed
during different in vitro and in vivo infection-relevant conditions.
In this regard, RNA-seq-based transcriptome analysis of mouse
macrophages infected in vitro with two UPEC strains, allowed to
identify strain-specific differentially expressed genes associated
to the survival in macrophages, such as those involved in the
responses to oxidative stress, as well as those involved in the
initial adhesion of UPEC to cells, such as multiple flagella genes
(Mavromatis et al., 2015). Moreover, the global gene expression
of different UPEC strains has been investigated by RNA-seq of
urine samples collected fromUTI patients. These transcriptomics
studies defined the global transcription profile for UPEC during
UTI, highlighted the high genomic diversity of different UPEC
strains, and confirmed, on a global scale, the expression during
UTI of several genes encoding virulence factors. In fact, it has
been observed the transcription of genes associated with the
UPEC’s adhesion to the uroepithelium (type 1 and P pili),
of genes involved in iron uptake (enterobactin, aerobactin,
yersiniabactin, and salmochelin), of genes encoding toxins
(hemolysins nad cytotoxic factors), as well as those involved in
copper efflux (Bielecki et al., 2014; Subashchandrabose et al.,
2014).
High-resolution liquid chromatograph-mass
spectrometry/mass spectrometry (LC-MS/MS)-based technology
has been applied to identify and characterize the surface
proteome of UPEC isolates and of strains grown in human
urine (Wurpel et al., 2015, 2016). These studies identified several
expressed proteins highly conserved among different strains,
thus representing the core surface proteome of UPEC. UPEC
core surface proteins, such as integral Outer Membrane (OM)
proteins (e.g., OmpA, OmpC, OmpF) and several iron-uptake
proteins, were in fact detected in more than 80% of strains
(Wurpel et al., 2015). Clearly, characterization of those UPEC
surface proteins that are conserved among different strains
and immunogenic is an essential step for identifying potential
vaccine candidates and new therapeutic targets (Cash, 2014).
Moreover, new insights into spatial changes in the UPEC
proteome under experimental conditions mimicking bacterial
growth in the urinary tract, have been provided by MALDI TOF
IMS-based proteome profiling of differentially expressed proteins
within UPEC biofilms. The application of this technique, that
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allows for in situ two-dimensional assessment of protein spatial
distribution and abundance, revealed the occurrence of different
bacterial subpopulations within biofilms: a type-1 pili-expressing
cells localized at the air-exposed region and a curli-equipped
population localized to the underlying air-liquid interface (Floyd
et al., 2015).
Together, all the above mentioned “omics” approaches have
allowed a great deal of new information to be available and
that is enabling a more comprehensive understanding of UPEC’s
pathogenic mechanisms.
THE BLADDER EPITHELIUM SHOWS
SELF-DEFENSE MECHANISMS AGAINST
INVADING BACTERIA
The most commonly targeted site of UTIs is the bladder. The
bladder epithelium possesses powerful barriers and the BECs
show antibacterial activities. Despite their properties, BECs and
the bladder epithelium are often circumvented by UPEC (Wu
et al., 2017). As discussed, the progressive ascending colonization
of bacteria contaminates the urethra and the origin of this
infection is usually from the gut (Kaper et al., 2004). Owing to the
presence of urine, that represents an ideal growth broth, bacteria
proliferate in a relatively short time lapse, while the flushing of
urine during urination removes most of the invading bacteria.
However, bacterial strains are able of binding tightly to BECs
lining the bladder using fimbrial organelles (Duncan et al., 2004;
Chahales and Thanassi, 2015).
The multilayered bladder epithelium is also known as
“transitional epithelium” and it is composed by three layers:
basal cell layer (5–10 µm in diameter), intermediate cell layer
(20 µm in diameter), and superficial apical layer with large
hexagonal cells (diameters of 25–250 µm), which are also termed
“umbrella cells.” A basementmembrane lies underneath the basal
epithelium (Figures 3A,F). The umbrella cells play a prominent
role in maintaining a barrier against most substances found in
urine, and show a number of properties, including specialized
membrane lipids, asymmetric unit membrane particles, and a
plasmalemma with stiff plaques. These plaques may cover up
to 90% of the urothelial cell surface, with each plaque being
composed of nearly 1,000 subunits. These subunits are made by
proteins (uroplakins, UPs), which serve as themajor receptors for
UPEC adherence to the host cell and are localized within plaques
on the apical membranes of the mature umbrella cells (Veranic
et al., 2004). There is a correlation between the glycosylation
changes in UPs and the different pathological conditions of
the urothelium such UTI and interstitial cystitis (Birder, 2005;
Katnik-Prastowska et al., 2014; Habuka et al., 2015).
The fusiform vesicles (FVs) are unique cytoplasmic organelles
contained in the umbrella cells. FVs deliver preassembled
crystalline arrays of UP proteins to the apical cell surface
of urothelial umbrella cells. Different Rab GTPases function
as regulators of specific steps in membrane traffic pathways
and are localized to the cytosolic face of specific intracellular
membranes. Rab27b, is a small GTPase regulating intracellular
vesicle movement which is expressed at an extraordinary high
level (0.1% of total protein) in urothelium. The Rab27b+ FVs are
involved in the storage of extra membrane which are necessary
when urine accumulates and causes bladder expansion (Wankel
et al., 2016). In order to enter epithelial cells, UPEC coopt the
superficial epithelial cells by expoiting their bladder volume-
regulating properties by stimulating the exocytosis of fusiform
vesicles right where the bacterial attach. The adherent bacteria
are then internalized when these membranes are subsequently
retracted into cells (Figure 3B; Wu et al., 2017). UPEC have
been found to reside within Rab27b/CD63/Caveolin-1-positive
fusiform vesicles (O’Brien et al., 2016). Internalized UPEC
become encased in Rab27b+ fusiform vesicles within the
cytosol of the superficial epithelium (Figure 3B; Bishop et al.,
2007). Replication of internalized UPEC bacteria rapidly occurs,
resulting in the maturation of IBCs, a structure that possesses
biofilm-like properties which is protected from innate defenses
and antibiotics (Justice et al., 2006; Goller and Seed, 2010). Fusion
with lysosomes is thus impaired, because internalized bacteria are
mostly encased in Rab27b+ compartments.
Defense mechanisms of bladder epithelial cells against
intrusion of bacterial include receptors such as toll-like receptors
(e.g., TLR2, TLR4, TLR5, and TLR11) that are able to promptly
recognize intruding bacteria (Larue et al., 2013). After UPEC
encapsulation within RAB27b+ vesicles in BECs, intracellular
UPEC are recognized by TLR4 which increases intracellular
cyclic AMP (cAMP) levels (Figure 3B). This triggers the
exocytosis of RAB27b+ vesicles harboring UPEC and the
intracellular bacterial expulsion back into the bladder lumen
(Figure 3C).
However, some UPEC break the RAB27b+ vacuole and
cannot be expelled into the urine; thus, these bacteria are
targeted by autophagy and delivered into the lysosomes, where
they actively neutralize the pH by reducing their acidicity
and degradative potential (Abraham and Miao, 2015). These
malfunctioning lysosomes are sensed by a lysosomal transient
receptor potential mucolipin 3 Ca2+ channel (TRPML3), which
is localized on the membrane of lysosomes (Miao et al., 2015).
The activation of this Ca2+channel rapidly fluxes out into
the cytosol the Ca2+ stored in the lysosome, which induces
the spontaneous expulsion into the extracellular space of the
defective lysosomes and its contents (Figure 3D).
Pathogen sensing by TLR4 induces the production of
various soluble factors which are secreted by BECs, including
antimicrobial peptides (AMP, such as cathelicidin and β-defensin
1; Sun et al., 2013; Chromek, 2015), antimicrobial proteins [such
as pentraxin 3 (PTX3); (Uzun et al., 2016)] and chemokines [such
as CXC-chemokine ligand 1 (CXCL1) and CC-chemokine ligand
5 (CCR5); Schiwon et al., 2014; Figure 3E]. Attachment to the
urothelium or bacterial lysis are inhibited by these antimicrobial
peptides, which are also induced when bacteria succeed to attach
to the urothelium (Spencer et al., 2014). Moreover, excretion
in the urine of uromodulin, a major high mannose-containing
glycoprotein, exerts a protective effects against UTI by competing
with the binding of UPEC FimH to uroplakin Ia (Pak et al., 2001).
When all these export mechanisms fail to clear the urothelium
from the invading UPEC, BECs activate the last line of defense.
Acute infections are commonly associated with of the exfoliation
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FIGURE 3 | The innate immune responses of bladder epithelium to bacterial infections. (A) The bladder epithelium; (B) adherent bacteria are internalized along with
Rab27b+ fusiform vesicles; (C) exocytosis of RAB27b+ vesicles harboring UPEC and expulsion of the intracellular UPEC back into the lumen of the bladder; (D)
transient receptor potential mucolipin 3 Ca2+ channel (TRPML3) triggers the spontaneous expulsion of the defective lysosomes and its contents out into the
extracellular space; (E) soluble factors are also secreted by BECs, including antimicrobial peptides (AMP, such as cathelicidin and β-defensin 1), antimicrobial proteins
[such as pentraxin 3 (PTX3)] and chemokines [such as CXC-chemokine ligand 1 (CXCL1) and CC-chemokine ligand 5 (CCR5)]. (F) Exfoliation is accompanied by rapid
renewal of superficial BECs through active proliferation of basal progenitor mast cells. Intimate crosstalk between macrophages ensures the precise initiation of
neutrophil responses.
of the epithelium, with the loss of a large numbers of superficial
epithelial cells. Exfoliation is followed by an efficient restoring of
superficial BECs through active proliferation of basal progenitor
mast cells (MCs). BECs exposed to UPEC release copious
amounts of interleukin-1β (IL-1β) that regulates migration of
multiple cell types including neutrophils and MCs (Choi et al.,
2016). Exfoliation is also triggered by caspase 3- and caspase
8-dependent apoptosis of infected BECs, which shed into the
bladder lumen (Figure 3F). However, exfoliation, which is an
efficient host defense strategy, may is some cases favor the
dissemination of bacteria, by clearing the way to deeper tissues.
Indeed, the death of the superficial epithelium is intentionally
induced by certain virulent UPEC to better reach deeper tissue
where intermediate BECs are located and where they form QIRs
and where they can persist for extended period of time. Actually,
one of the main reason for high rate recurrence of infections
in the bladder and resistance to antibiotics is associated to the
presence of QIRs within subepithelium (Leatham-Jensen et al.,
2016).
The immune system operates with different and specific
strategies to reduce inflammation and to preserve tissue integrity.
The direct phagocytosis of bacteria is operated by neutrophils
that also clear bacteria through extracellular burst of ROS, which
are highly toxic to bacteria (Aubron et al., 2012). Intimate
crosstalk between LY6C− and LY6C+ macrophages ensures
the precise initiation of neutrophil responses (Figure 3E).
Local LY6C− macrophages release CC-chemokine ligand 2
(CCL2), CXC-chemokine ligand 1 (CXCL1) and macrophage
migration inhibitory factor (MIF) to recruit LY6C+macrophages
and neutrophils from the bloodstream (Schiwon et al., 2014;
Figure 3F). LY6C+ macrophages, as a consequence of infection
sensing, secrete tumor necrosis factor (TNF), which acts on
local LY6C− macrophages to trigger their production of
CXCL2. The last is responsible for spontaneously production
of matrix metalloproteinase 9 (MMP9) by neutrophils and
their transepithelial movement (Nathan, 2006). The resident
LY6C− macrophages play a major role as the main pro-
inflammatory cells, whereas the recruited LY6C+ macrophages
keep neutrophils in close proximity before targeting the pathogen
(Abraham and Miao, 2015).
UPEC ANTIBIOTIC SUSCEPTIBILITY AND
RESISTANCE
The efficacy of antibiotic treatment depends on the identification
and antimicrobial resistance pattern of uropathogens responsible
for UTI (Bartoletti et al., 2016). The practice of prescribing
antibiotics to treat UTI without bacterial characterization led
to increased resistance among uropathogens and to decreased
effectiveness of oral therapies. Despite clinical symptoms of
UTIs have been ameliorated by numerous antibiotics, UPEC
persistence and resistance to antibiotics represent a serious
problem (Blango and Mulvey, 2010). According to the 2015
guidelines of the European Association of Urology, the
recommendations for the prevention of recurrent UTI are first
aimed at behavioral changes and immediately after toward non-
antibiotic measures. If these two recommendations are not
sufficiently effective then the antibiotic prophylaxis should be
considered, in order to prevent the adverse events and collateral
damages that the long-term and not necessary use of antibiotics
may cause (Vahlensieck et al., 2016). In Europe, resistance
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to UPEC isolates shows average values of 11.8% for third-
generation cephalosporins and 22.3% for fluoroquinolones. In
the U.S., fluoroquinolone-resistant UPEC represented the 31.3%
of isolates among hospitalized patients between the years 2007
and 2010 (Edelsberg et al., 2014). These data confirm the general
consideration that number of effective antibiotic compounds
availability and the prevalence of antibiotic resistance are
worsening, as demonstrated by an increased number of clinical
studies (Bartoletti et al., 2016).
Antimicrobial prophylaxis for women with recurrent UTI
include, for example, 50mg or 100mg of nitrofurantoin once
a day; 100mg of Trimethoprim (TMP) once a day; 40/200mg
TMP/sulfamethoxazole (co-trimoxazole) once a day or three
times a week; 3 g of fosfomycin trometamol every 10 days
and, during pregnancy, for example, 125–250mg of cephalexin
or cefaclor 250mg once a day (Grabe et al., 2015; Giancola
et al., 2017). Among other antibiotics, imipenem represents
the best efficient antibiotic against all UPEC strains (100%),
followed by ertapenem (99.98%), amikacin (99.94%), and
nitrofurantoin (99.91%). Carbapenems like imipenem represent
the best option for the treatment of extended-spectrum beta-
lactamase (ESBL) strains (Idil et al., 2016). UPEC strains are
also susceptible to ciprofloxacin (Tosun et al., 2016), cefotaxime,
piperacillin/tazobactam (Dizbay et al., 2016), azithromycin,
doxycycline and ceftriaxone (Saha et al., 2015). However, several
UPEC isolates are resistant to ampicillin, oral first-generation
cephalosporins, TMP-sulfamethoxazole (Moya-Dionisio et al.,
2016), cefuroxime (Chang et al., 2016), cotrimoxazole (Saha
et al., 2015), amoxicillin-clavulanate, nalidixic acid, cefradine,
and aminopenicillins (Narchi and Al-Hamdani, 2010). In some
cases, the combined effect of different antibiotics prompted a
significant increment in susceptibility, as found for triclosan with
amoxicillin and gentamicin (Wignall et al., 2008). A retrospective
analysis has identified ciprofloxacin as the most used antibiotic
for empirical therapies (76% of cases; Parish and Holliday,
2012).
Due to ecological side effects, the oral cephalosporins
and fluoroquinolones are no longer recommended as routine
treatments, except for specific clinical situations. Furthermore,
the worldwide increment of UPEC strains resistant to TMP
questions its use with or without a sulfonamide as an effective
prophylactic agent (Idil et al., 2016). High urinary levels of
levofloxacin are not enough to cure UTIs and the combination
of ceftolozane/tazobactam was more effective as an alternative
treatment in settings of increased fluoroquinolone resistance
(Huntington et al., 2016). Increased resistance of UPEC strain
isolates against ampicillin (96.42 %), tetracycline (85.71 %),
amikacin (71.42 %), ciprofloxacin (67.85 %), and gentamycin
(58.71 %) has been found in pregnant women with history
of recurrent UTIs (Habibi and Khameneie, 2016). Finally,
numerous government agencies advise against the long-term
use of prophylactic nitrofurantoin because of rare but serious
pulmonary and hepatic adverse effects (Vahlensieck et al., 2016).
New antibiotics, such as colistin (Cui et al., 2016), finafloxacin,
and cefiderocol (S-649266), which are currently in early clinical
development, might be useful in the treatment of UTIs (Zacché
and Giarenis, 2016).
Figure 4 shows the structure formulae of the most
representative antibiotics for which UPEC resistance has been
demonstrated (red background) and those showing susceptibility
to UPEC (green background). The yellow background shows
antibiotics that already show resistance in some UPEC strains.
ALTERNATIVE ANTIMICROBIAL REMEDIES
Antibiotics will continue to be an unavoidable source for the
prevention of UTIs on a case-by-case basis. However, the
excessive use of antibiotics and the long-term interference with
intestinal microbiota, require to search for alternative remedies.
A plethora of molecules has been tested to reduce UPEC
infections by exploiting their ability either to stimulate the
immune system or to interfere with the UPEC ability to adhere
and invade the urothelium. Here we briefly summarize the most
effective alternative remedies to fight UPECs.
Vaccines
The development of new strategies to fight UTI has focused
on the development of vaccines based on bacterial components
with the aim of identifying specific UPEC factors for potential
use as vaccine antigens (McLellan and Hunstad, 2016). Among
candidate antigens, potential targets are adhesins, antimicrobial
peptides (AMPs), and siderophores (Spaulding and Hultgren,
2016). However, the use of vaccines may alter the proteobacteria
populations of E. coli in the gut and may find a difficult way
to reach the bladder lumen. Furthermore, vaccine use might be
more efficient to treat upper rather than lower urinary tracts
(McLellan and Hunstad, 2016). Recently, healthy adult women
with a history of recurrent UTI where the subject of a multicentre
phase 1b trial where a single intramuscular injection of either a
bioconjugate vaccine containing the O-antigens of four E. coli
serotypes (ExPEC4V) or placebo were administered. Vaccination
induced significant IgG responses for all serotypes; moreover,
the vaccine group showed significantly lower UTIs caused by
UPEC of any serotype when compared with the placebo group
(Huttner et al., 2017). In a meta-analysis of about 900 patients,
the oral vaccine OM-89 (Uro-Vaxom R©) reduced the mean
number of UTIs by half, whereas a vaginal vaccine (Urovac)
showed a scanty reduction in recurrent UTIs and caused a
vaginal irritation in nearly 28% of patients (Beerepoot et al.,
2013). An alternative strategy to elicit protective immunity is
to select as antigens small molecules, rather than proteins or
peptides. The use of siderophore-protein conjugates was found
to elicit immune responses targeted to bacterial siderophores
and to successfully protect against UTI (Mike et al., 2016). A
reverse-vaccinology approach in combination with proteomics
and genomics was used to identify putative broadly protective
vaccine antigens (Moriel et al., 2016). Currently, no UTI vaccines
are approved in the United States but among current strategies,
immunotherapeutic formulation OM-89 (marketed in Europe by
EurimPharm GmbH as UroVaxom), which is a bacterial extract
prepared from 18 strains of E. coli, is really promising (Neto et al.,
2016). The identification of potential vaccine targets has been
recently reviewed (O’Brien et al., 2016; Poolman and Wacker,
2016).
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FIGURE 4 | Structure formulae of some UPEC resistant and susceptible antibiotics. UPEC resistance is shown with a red background, susceptibility with a green
background, whereas the yellow background shows antibiotics that already show resistance in some UPEC strains.
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Probiotics
Women with recurrent UTIs often show alterations in their
vaginal or periurethral microbiota (Czaja et al., 2009). Probiotics
have been extensively used as alternative approaches to reduce
recurrent UTIs (Zacché and Giarenis, 2016). Several Lactobacilli
strains showed UPEC inhibitory activity between that of sensitive
and resistant antibiotics (Shim et al., 2016). One of the major
roles of Lactobacilli is their ability to clear potential UPEC
reservoirs, thus preventing recurrences. Lactobacillus-mediated
protection from UTI is not clear, and may involve hydrogen
peroxide, surfactants, and anti-adhesive molecules production
(O’Brien et al., 2016). However, contrasting results have been
reported. For instance, Lactobacilli prophylaxis did not decrease
the rate of UTI recurrence in several open randomized trials with
women who had a UTI caused by UPEC (Kontiokari et al., 2001;
Beerepoot et al., 2013; Schwenger et al., 2015). On the other hand,
Lactobacilli were shown to actively stimulate the immune system
by up- and down-regulation of NF-κB activity (Karlsson et al.,
2012), and to colonize and protect the vagina (Reid, 2000), thus
suggesting some sort of indirect-cooperative function.
Estrogens
The vaginal epithelium and its acidic microenvironment
provide substantial inhibition of bacterial growth of enteric
microorganisms. Estrogen is an important modulator of
urothelium cell growth and differentiation. Estrogen may
constitute a risk factor for infections in young women; however,
after menopause the low estradiol levels have been related to
recurrent infections (Mody and Juthani-Mehta, 2014). Estrogen
application modulates two epithelial defense mechanisms:
induction of AMPs and reduction of epithelial exfoliation (Luthje
et al., 2013). Furthermore, increased epithelial integrity and
higher expression of AMPs may reduce the formation of QIRs
as the source of recurrent infections (Luthje and Brauner,
2016). However, oral estrogen therapy failed to be effective
at reducing UTI risk compared with placebo, whereas vaginal
estrogen application reduced UTI (Perrotta et al., 2008; Matulay
et al., 2016). Vaginal estrogen therapy was found to be effective
in preventing recurrent UTI of postmenopausal women when
used in combination with hyaluronic acid, chondroitin sulfate,
curcumin, and quercetin administered per os (Torella et al.,
2016).
Pilicides and Curlicides
The requirement of pili for adhesion by UPEC makes inhibitors
of the assembling chaperone-usher pathway (CUP) as potential
targets to reduce UTI (Aberg and Almqvist, 2007). Therefore,
pilicides represent an interesting alternative to antibiotics. Two
classes of pilicides have been developed: amino acid derivatives
and pyridinones (Svensson et al., 2001). In laboratory and clinical
E. coli strains, these compounds have been demonstrated to be
able to reduce by almost 90% hemagglutination mediated by
either type 1 or P-pili adherence to BECs and biofilm formation
mediated by type I pili (Pinkner et al., 2006). One of these
pilicides, ec240, was found to decrease motility and dysregulate
CUP pili, including type 1, P, and S pili (Greene et al., 2014).
Curli-mediated biofilm formation requires a specific assembly
machinery (Chapman et al., 2002). Curlicides are inhibitors of
both type 1 pilus production and curli biogenesis. Compounds
derived from the peptidomimetic scaffold that show pilicide
activity can prevent both Aβ aggregation and curli formation
(Chorell et al., 2011). A small-molecule curlicide (FN075) was
shown to inhibit both type 1 pilus production and curli biogenesis
by reducing the biofilm and virulence of UPEC in a mouse model
of experimental cystitis (Cegelski et al., 2009).
Figure 5 depicts the chemical structure of some pilicides and
curlicides.
D-Mannose and D-Mannose-Derived FimH
Antagonists
One of the main strategies to reduce UPEC infection is targeting
bacterial adhesion by inhibiting, for instance, FimH. By using
FIGURE 5 | Structure formulae of pilicide scaffold, some bioactive pilicides, and the curlicide FN075.
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FIGURE 6 | Structure formulae of D-mannose and some bioactive mannosides.
catch bond binding mechanisms, UPEC Type I fimbriae FimH
binds terminal epitopes of high mannose and paucimannosidic
glycans conjugated to uroplakin Ia which are located on the
surface of urothelial cells (Sauer et al., 2016). The x-ray crystal
structures of FimH bound to α-D-mannose, and mannose
derivatives have been used to rationally design specific FimH
inhibitors (Han et al., 2012). D-Mannose (Figure 6) is involved
in the glycosylation of some proteins; this molecule is a C-
2 epimer of D-glucose that play several roles in the human
metabolism. Mutation in enzymes involved in the mannose
metabolism induces certain glycosylation disorders (Gordon,
2000). The use of D-Mannose as a dietary supplement has the
intent of influencing the glyconutrient status and improve human
health (Hu et al., 2016). In both in vivo and in vitro studies, the
transport rate of D-mannose across the intestine was found to be
approximately one tenth that of D-glucose (Duran et al., 2004).
D-mannose can bind proteins to induce macrophage activation
and interleukin-l release (Hu et al., 2016), but its most important
action with respect to UTI is the capability to saturate FimH
adhesin by blocking the invariant lectin pocket (O’Brien et al.,
2016; Zacché and Giarenis, 2016). However, side effects of D-
mannose have been reported underscoring the importance of
stringent regulation of D-mannose metabolism, particularly for
a subset of pregnant women (Freinkel et al., 1984; Sharma et al.,
2014a,b). The only published clinical study on D-mannose effect
in UTIs reduction indicates similar effects of nitrofurantoin,
with no significant side effects when compared to the antibiotic
treatment. However, this study suffers of a low number of
recruited patients (Kranjcec et al., 2014).
Mannosides are small-molecular weight molecules that are
orally bioavailable and show inhibiting action toward the FimH
adhesion; murine models show that these molecules are highly
efficacious in the treatment of UTI (Cusumano et al., 2011;
Han et al., 2012). Mannosides are a cost-effective treatment able
to lower the antibiotic resistance rate and represent interesting
therapeutic compounds for the treatment and prevention of
UTIs (Kostakioti et al., 2012). For instance, several mannosides
(Figure 6) are able to attenuate UPEC virulence through the
blockage of FimH binding to BECs. This binding prevents
bacterial adherence, invasion, and IBC formation (Han et al.,
2010).
FIGURE 7 | Structure formula of 25-hydroxyvitamin D3.
FIGURE 8 | Structure formulae of methenamine mandelate and hippurate.
Vitamin D
As discussed above, AMPs exhibit alternative functions and
play an important supporting role in the immune system. The
human antimicrobially-active AMP cathelicidin is made by 37
amino acids and is referred to as LL-37 because of the starting
with two lysin residues. LL-37 binds Curli fimbriae of UPEC
and prevents interaction with the bacterial cell membrane (Kai-
Larsen et al., 2010). The transcription factor vitamin D receptor
(VDR) is a direct target of the gene that encodes for cathelicidin
antimicrobial peptide (CAMP) and up-regulation of CAMP is
induced by VDR in response to 25-hydroxyvitamin D3 (vitamin
D3, Figure 7) and its analogs (Gombart et al., 2005). Therefore,
Vitamin D has the potential to protect the urinary tract against
infection by modulating the production of AMPs. Both pediatric
and premenopausal studies revealed that Vitamin D deficiency
correlates with a higher frequency and severity of UTI (Nseir
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FIGURE 9 | Structure formulae of some polymeric phenolics.
FIGURE 10 | Structure formulae of some non-polymeric phenolics.
et al., 2013; Hacihamdioglu et al., 2016), suggesting a promising
role of vitamin D as a potential complement in the prevention of
UTI (Hertting et al., 2010; Luthje and Brauner, 2016).
Methenamine
Methenamine, when used in combination with mandelic or
hippuric acid (Figure 8) is used for the treatment of UTIs
(Cronberg et al., 1987). In the urine, the presence of acidifying
substances (such as organic acids and Vitamin C) lowers the pH
(≤ 6.0) and decomposesmethenamine to form formaldehyde and
ammonia, the former exhibiting an aspecific bactericidal effect.
Because of some adverse effects (mainly chemically-induced
hemorrhagic cystitis in overdose), the use of this compound
has been reduced. However, because of the recurrence of UTI
and the increased antibiotic resistance of UPEC, methenamine
has been re-introduced in substitution to the use of daily
antibiotic prophylaxis. Moreover, methenamine was not found to
contribute to overall increase in resistance and can be generally
considered as safe and well-tolerated (Matulay et al., 2016).
Phenols and Polyphenols
Phenolic compounds exert a strong antibiotic effect and can
be generally subdivided into polymeric and not polymeric
phenolics.
Polymeric Phenolics
Among polymeric phenolics, proanthocyanidins (PACs)
represent an interesting class of compounds. These tannins are
produced by different plants and those isolated from cranberry
(Vaccinium macrocarpon) are particularly rich in A-type linkages
(PAC-A), compared to the more common B-type linkages of
other proanthocyanidins (PAC-B; Figure 9; Chughtai et al.,
2016). PACs-A were found to inhibit P-fimbrial adhesion in vitro
and to play a significant role in UTI prevention (Howell et al.,
2005; Silverman et al., 2013; Occhipinti et al., 2016). Despite the
considerable number of scientific and clinical studies to support
efficacy of cranberry extracts in reducing UTI, inconsistency
in meta-analysis methodologies, clinical heterogeneity (i.e.,
participants, the result and the intervention) and methodology
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FIGURE 11 | Structure formulae of some representative bioactive compounds isolated from plant extracts exerting antimicrobial activity against UPEC listed in
Table 1.
(i.e., the trial design and execution and inclusion/exclusion
criteria) along with the poor characterization of the cranberry
extract used may lead to different results and interpretations, as
recently pointed out (Chrubasik-Hausmann et al., 2014; Liska
et al., 2016; Nicolle, 2016). Cranberry extracts containing 72mg
PAC-A produce an active and significant bacterial anti-adhesion
in human urine (Howell et al., 2010; Micali et al., 2014; Singh
et al., 2016); however, the mechanism by which PACs-A exert
their anti-adhesive action is not yet clear. For instance, the
conserved lipid A moiety of LPS are preferentially recognized by
PACs, enabling them to bind LPS from multiple Gram-negative
bacterial species (Delehanty et al., 2007). Recently, a standardized
cranberry extract particularly rich in PAC-A and its purified
PAC-A fractions were tested for their antiviral activity against
Herpes 1 and Herpes 2. By using a combination of molecular
and biochemical analyses, Terlizzi and co-workers were able to
show that PAC-A was able to specifically target viral glycoprotein
gD and gB, thus causing the inability of viral particles to infect
target cells (Terlizzi et al., 2016). These new findings open the
possibility that PAC-A may not only target the FimH lectins
as D-mannose. Recently, adherence of UPEC to the bladder
was enhanced in the surfactant protein A (SP-A)-deficient
mice; therefore, SP-A may play an important role in innate
immunity against UPEC (Hashimoto et al., 2017). Because
dimers and trimers of PAC-A can enter the bloodstream (Foo
et al., 2000; Feliciano et al., 2012, 2014; Zhang et al., 2016)
they can potentially reach urothelial cells. Owing to the ability
of these polyphenols to enter the cells and actively interact
(Menghini et al., 2011; Vu et al., 2012) it is conceivable to argue
the possibility of a PAC-A effect on SP-A, limiting bacterial
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FIGURE 12 | The four main areas representing the Strengths and the Weaknesses of UPEC, the Opportunities for alternative remedies to antibiotics and, finally, the
Treats that UPEC cause to human health.
adherence. However, further studies are necessary to dissect the
role of PAC-A in UTIs reduction.
Green tea extracts are also rich in polyphenols, with catechins
(Figure 9) being the most active components. The antimicrobial
activity of green tea against UPEC was correlated to the ability of
catechins to be excreted in the urine at concentrations enough to
reduce the UTI (Reygaert and Jusufi, 2013), and this hypothesis
was confirmed by intravescical instillation on a rat model of
bacterial cystitis (Rosenberg et al., 2014).
Non-polymeric Phenolics
One of the cellular mechanisms that increase resistance to UPEC
invasion of BECs is the inactivation of the Rac1-GTPase and
the activation of the adenylyl cyclases, the latter catalyzing
the conversion of ATP to cAMP (Bishop et al., 2007; Song
et al., 2007). Some non-polymeric flavonoids such as quercetin,
luteolin, scutellarein, phloretin, and genistein, are present in
the diet and are excreted in the urinary system (Wang et al.,
2016). These compounds inhibit the activity of cAMP and
cyclic nucleotide phosphodiesterases (PDEs; Kuppusamy and
Das, 1992) and are considered as potential non-antibiotic
therapeutic agents in UTI setting. Quercetin has a wide range
of biological properties and has been used to prevent interstitial
cystitis (Theoharides et al., 2008). Luteolin, by interfering with
PDE activity, inhibits lymphocyte function-associated antigen-
1 (LFA-1) expression and neutrophil adhesion to endothelial
cells, thus acting as an antinflammatory agent (Jiang et al.,
2015) and a protectant of bladder epithelial cells against UPEC
(Shen et al., 2016). Furthermore, this flavone inhibits UPEC-
induced cytotoxicity and decreases both attachment and biofilm
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formation in pre-treated UPEC (Shen et al., 2014). Bacterial
fatty acid synthesis, in particular β-ketoacyl acyl carrier protein
synthase (KAS) enzymes, are good therapeutic targets for
novel antibiotics. In silico studies revealed that binding energy
toward KAS I active site of the flavonoinds genistein and
isorhamnetin can be used as potential drug candidates against
UPEC (Figure 10) (Sabbagh and Berakdar, 2015).
Other non-polymeric phenolic exert antiadhesive properties.
Trans-cinnamaldehyde is able to down-regulate the expression of
some UPEC genes involved in attachment and invasion of host
tissue. This compound was found to significantly decrease UPEC
attachment and BECs invasion (Amalaradjou et al., 2011).
Other Medicinal Plants with Antibacterial
Activity against UPEC
Several studies report the antibacterial activity of plant extracts,
particularly in in vitro studies (Luthje and Brauner, 2016). In
the majority of these studies, the failure to identify the main
compound responsible for the reduction of UPEC adhesion or
any other possible mechanism involved in alleviation of UTI
makes these studies interesting from a general phytochemical
viewpoint, but less useful to the understanding of mechanism of
action. Table 1 summarizes the effects of different plant extracts
on UTI and reduction of UPEC infection and adhesion to BECs.
Figure 11 shows the structure formulae of some bioactive
compounds against UPEC listed in Table 1.
CONCLUDING REMARKS
Uropathogenic Escherichia coli infections pose a serious problem
to human health, with societal costs of tens of billion US$
worldwide. The increased resistance to both synthetic and natural
antibiotics causes recurrence and chronicity of infection, with
the emergence of new and more serious illnesses. There are both
direct and indirect strategies against UPEC infections. Direct
strategies are targeting bacteria viability, bladder epithelium
adhesion and biofilm formation; indirect strategies elicit and
enhance immune responses, by stimulating infected tissues and
cells to overreact to UPEC invasion.
In this review, we provided a comprehensive picture of the
UPEC infection, with the aim of giving the reader elements
from both sides of the problem: the pathogen infectivity
and the human cell response. The ongoing search for new
and more effective antibiotics and the discovery of natural
products from plants, fungi and non-pathogenic bacteria shall
consider the multiple aspects of UPEC infection. Figure 12
summarizes the four main areas representing the Strengths and
the Weaknesses of UPEC, the Opportunities for alternative
remedies to antibiotics and, finally, the Treats that UPEC
cause to human health. While antibiotics will remain the main
drugs to reduce infections, alternative chemicals may offer
the opportunity to (a) by-pass antimicrobial resistance and
(b) show multi-targeted action, with the potential of targeting
both the UPEC and the innate immune system. We cannot
exclude that new therapies may include both antibiotics and
natural products altogether, as recently demonstrated (Vadekeetil
et al., 2016). An increasing body of evidence shows that
reduction of adhesion of UPEC to urinary tract tissues reduces
recurrence and increases recovery. Future interesting targets
might not only be directed to UPEC adhesins, but also to
immune-based strategies able to improve cell responses to
UPEC infection; in this context, several natural products fit this
strategy.
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